Verhaegh GW - Search Results

1

Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.

Hamid AR, Pfeiffer MJ, Verhaegh GW, Schaafsma E, Brandt A, Sweep FC, Sedelaar JP, Schalken JA. Hamid AR, et al. Among authors: verhaegh gw. Mol Med. 2013 Jan 22;18(1):1449-55. doi: 10.2119/molmed.2012.00296. Mol Med. 2013. PMID: 23196782 Free PMC article.

2

Differential expression of vimentin in rat prostatic tumors.

Bussemakers MJ, Verhaegh GW, van Bokhoven A, Debruyne FM, Schalken JA. Bussemakers MJ, et al. Among authors: verhaegh gw. Biochem Biophys Res Commun. 1992 Feb 14;182(3):1254-9. doi: 10.1016/0006-291x(92)91866-o. Biochem Biophys Res Commun. 1992. PMID: 1540169

3

DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. Bussemakers MJ, et al. Among authors: verhaegh gw. Cancer Res. 1999 Dec 1;59(23):5975-9. Cancer Res. 1999. PMID: 10606244

4

Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene.

Verhaegh GW, van Bokhoven A, Smit F, Schalken JA, Bussemakers MJ. Verhaegh GW, et al. J Biol Chem. 2000 Dec 1;275(48):37496-503. doi: 10.1074/jbc.M006293200. J Biol Chem. 2000. PMID: 10982808 Free article.

5

DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.

de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. de Kok JB, et al. Among authors: verhaegh gw. Cancer Res. 2002 May 1;62(9):2695-8. Cancer Res. 2002. PMID: 11980670

6

New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene.

Schalken JA, Hessels D, Verhaegh G. Schalken JA, et al. Urology. 2003 Nov;62(5 Suppl 1):34-43. doi: 10.1016/s0090-4295(03)00759-3. Urology. 2003. PMID: 14607216 Review.

7

Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.

Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. Grabmaier K, et al. Among authors: verhaegh gw. Oncogene. 2004 Jul 22;23(33):5624-31. doi: 10.1038/sj.onc.1207764. Oncogene. 2004. PMID: 15184875

8

Applicability of biomarkers in the early diagnosis of prostate cancer.

Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Hessels D, et al. Among authors: verhaegh gw. Expert Rev Mol Diagn. 2004 Jul;4(4):513-26. doi: 10.1586/14737159.4.4.513. Expert Rev Mol Diagn. 2004. PMID: 15225099 Review.

9

The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines.

van der Heijden AG, Jansen CF, Verhaegh G, O'donnell MA, Schalken JA, Witjes JA. van der Heijden AG, et al. Eur Urol. 2004 Nov;46(5):670-4. doi: 10.1016/j.eururo.2004.06.009. Eur Urol. 2004. PMID: 15474281

10

Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.

van der Heijden AG, Verhaegh G, Jansen CF, Schalken JA, Witjes JA. van der Heijden AG, et al. J Urol. 2005 Apr;173(4):1375-80. doi: 10.1097/01.ju.0000146274.85012.e1. J Urol. 2005. PMID: 15758808

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

86 results

Search Page